Brief: Calithera Presents Interim Data From Phase 1B Trial Of Arginase Inhibitor CB-280 In Cystic Fibrosis At NACFC 2021

Calithera Biosciences

01/11/2021 11:12

Nov 1 (Reuters) - Calithera Biosciences Inc  CALA.O :
    * CALITHERA PRESENTS INTERIM DATA FROM PHASE 1B TRIAL
OF ARGINASE
INHIBITOR CB-280 IN CYSTIC FIBROSIS AT NACFC 2021
    * CALITHERA BIOSCIENCES INC - CB-280 WAS WELL-TOLERATED,
SHOWED
LINEAR PK AND DEMONSTRATED ROBUST DOSE-RELATED PD EFFECTS
    * CALITHERA BIOSCIENCES INC - STUDY IS ONGOING WITH COHORT 4
(300MG BID) ON TRACK TO COMPLETE ENROLLMENT BY END OF 2021

Source text for Eikon:  ID:nGNX5FV9tM 
Further company coverage:  CALA.O 

 ((Reuters.Briefs@thomsonreuters.com;))